Agenus BOT+BAL posts 21.2-month survival in refractory colorectal cancer
AI Summary- Agenus reported mature BOT+BAL Phase 1b results in 123 refractory MSS colorectal cancer patients.
- 21.2 months was median overall survival, with 33% three-year overall survival and 21% confirmed responses.
- Clinical Cancer Research published findings after three-year data were presented at ESMO GI Congress 2026.